Navigation Links
Our Lady of Lourdes Medical Center & The Heart House Participating in Research Study Using Adult Stem Cells for Chronic Cardiac Condition
Date:6/12/2013

Camden, New Jersey (PRWEB) June 12, 2013

Our Lady of Lourdes Medical Center and The Heart House are participating in a clinical study to determine whether a patient’s own (autologous), adult, stem cells are safe and can relieve chronic chest pain caused by coronary artery disease, as well as increase their ability to walk/exercise.

The RENEW study, sponsored by Baxter Healthcare Corporation and endorsed by the FDA to support a Biologic License Application for investigational CD34+ cell therapy, is a Phase III clinical trial to test the safety and efficacy of CD34+ stem cells. The study is being conducted at only 50 sites in North America and will involve approximately 440 patients.

The Principal Investigator, Vijay Verma, MD, FACC, and Sub-Investigator Andrew Zinn, MD, both interventional cardiologists with Cardiovascular Associates of the Delaware Valley (The Heart House), performed the first procedure at Our Lady of Lourdes Medical Center on April 25, 2013. The patient suffers from severe refractory angina, with two of the three arteries that supply oxygen to the heart completely blocked and is unable to undergo conventional revascularization.

“The patient suffers chest pain every day due to the blockages,” said Dr. Verma. “She has exhausted all other optimal therapies, including angioplasty, bypass surgery and enhanced external counter pulsation (EECP) to relieve the persistent chest pain.”

Patients enrolled in the study are randomly assigned to undergo the procedure or receive the standard of care. Patients in the procedure group are blindly randomized to receive either the stem cells or a placebo.

Forty-eight hours prior to the procedure, Dr. Verma conducted Apheresis procedure to selectively withdraw cells from the patient’s bloodstream. These cells were sent to a special lab where CD34+ cells were extracted and sent back to the hospital for injection into the patient’s heart. Derived from bone marrow, CD34+ cells are comprised of endothelial progenitor cells, which may be able to regenerate heart tissue and develop into new blood vessels. Previous Phase I & Phase II clinical trials have shown that the administration of the CD34+ cells were safe, and a reduction in chest pain and increased ability to exercise was noted in people with myocardial ischemia, or lack of oxygen flow to the heart tissue.

During the nearly four-hour procedure, Dr. Verma and his team created an electrical map of the patient’s heart to locate the damaged area they believed might be causing the chest pain. Using a catheter threaded through the patient’s groin area to the heart, Dr. Verma injected the patient’s CD34+ stem cells into areas of heart muscle with poor blood circulation. Neither Dr. Verma nor the patient knows if the stem cells or a placebo were injected until after the trial is completed and data has been obtained and evaluated.

“We will follow her for the next two years to see whether the injections improve her chest pain and her tolerance to exercise,” said Dr. Verma.

To learn if you are eligible to participate in the study, visit http://www.renewstudy.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10825425.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lourdes Doctors Urge Testing During Hepatitis Awareness Month
2. Lourdes Specialty Hospital Offers Unique Treatment Option for Medically Complex Patients with Hyperbaric Oxygen Therapy
3. Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend
4. Physician Groups Call for Fewer Medical Tests
5. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
6. CAM therapy combined with conventional medical care may improve treatment of lower back pain
7. Image share project gives patients and physicians anytime, anywhere access to medical images
8. Researchers determine vitamin D blood level for reducing major medical risks in older adults
9. Biomedical researchers receive Hartwell Foundation awards
10. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
11. Fitness in Middle Age Lowers Medical Costs Later: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... Mediaplanet is proud to announce the launch of ... treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage ... in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
(Date:11/30/2016)... U.K. (PRWEB) , ... November 30, 2016 , ... ... address the tech functions and stylish design wanted by today’s consumers at an ... Cronovo Co-Founder Darin Philip says the new watch is “a game changer” when ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology: